Coronary artery disease (CAD) is an important contributor to the cardiovascular burden in
cancer survivors. This review identifies features that could help guide decisions about the …

Chronologic age is the dominant risk factor for coronary artery disease but the features of
aging promoting coronary artery disease are poorly understood. Advances in human …

Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has
risen to become a prominent clinical challenge. This has led to the growth of the burgeoning …

Cardiovascular disease (CVD) and cancer are among the leading causes of morbidity and
mortality globally, and these conditions are increasingly recognized to be fundamentally …

For most acute myeloid leukemia (AML) patients an allogeneic hematopoietic stem cell
transplantation (HSCT) offers the highest chance of cure. The introduction of less toxic non …

Cancer and heart failure are the two leading causes of death in developed countries. These
two apparently distinct clinical entities share similar risk factors, symptoms, and …

Atherosclerotic cardiovascular disease is a growing threat among cancer patients. Not
surprisingly, cancer-targeting therapies have been linked to metabolic dysregulation …

Opinion statement Prophylaxis and treatment of thrombosis in leukemic patients still
represent a major challenge with several clinical questions yet to be solved. Indeed, the …

Addressing the need for more equitable cardio-oncology care requires attention to existing
disparities in cardio-oncologic disease prevention and outcomes. This is particularly …

Clinical treatment of acute myeloid leukemia (AML) largely relies on intensive
chemotherapy. However, the application of chemotherapy is often hindered by cardiotoxicity …